

From: Maruna, Thomas
Sent: Tuesday, March 10, 2015 4:42 PM
To: Allison Kennedy (akennedy@ebsi.com)
Cc: Scott, Dorothy; Fisher, Rob
Subject: Amendment Requested: (b) (4) - Please
Respond by
March 12, 2015

(b) (4) (b) (4)

Importance: High

Cangene Corporation [Emergent Biosolutions]
Attention: Ms. Allison Kennedy
March 10, 2015
Sent by email

Dear Ms. Kennedy:

We are reviewing your July 25, 2014 biologics license application (BLA) indicated for the treatment of toxemia associated with inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs for the following:

STN	Name of Biological Products
BL 125562	Anthrax Immune Globulin
Intravenous (Human)	

(b) (4)

(b) (4)

(b) (4)

If Cangene is unable to respond by March 12th, please propose an alternative date to respond.

The action due date for these files is March 25, 2014.

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP)CM
Lieutenant, U.S. Public Health Service
Senior Regulatory Management Officer
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Blood Research and Review
10903 New Hampshire Ave.
Silver Spring, MD 20993
thomas.maruna@fda.hhs.gov
O: (240) 402-8454
www.usphs.gov

"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.